wcg IRB

EXPERT & EFFICIENT

In 2000, WCG IRB expanded its services to include the administration of Institutional Biosafety Committees (IBCs), becoming the **first central IBC** in existence. Since 2000, we've registered over **1,000 IBCs** with the NIH on behalf of thousands of research sponsors, hospitals, clinics, and academic medical centers. Now, we are the **preferred and trusted** IBC partner for nearly **700 clinical trials and counting**.

WCG IBC review teams have experience in every category of molecular vaccine research and provide efficient, on-demand reviews for all clinical research subject NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules.

130+ Supported 130+ vaccine trials.

20+ Only major central IBC with 20+ years of experience.

700+ Reviewed 700+ studies since 2000.

1,000+ Worked with 1,000+ hospitals, clinics, and academic centers.

260+ Partnered with 260+ sponsors.

16 Operating in 16 countries.

WCG has **specific expertise** in IRB and IBC support for complex vaccine trials, including:

- Time-sensitive, seasonal indications
- Warm base site readiness for emerging infectious disease, pandemic response, and global health
- HIV, HCV, and bloodborne pathogens
- Just-in-time study startup
- Integration of naïve clinical trial sites
- Human infectious challenge studies
- mRNA, DNA, and viral vector vaccines

Through commitment to compliance and quality, we **reduce regulatory risks** for our clients. For example, we've **successfully passed 500+** required audits.

With efficient reviews and an integrated IRB and IBC solution process, we ensure **fast turnarounds** and provide **streamlined services**.

FDA ISO AAHRPP Association for the Accreditation of Human Research Protection Programs, Inc.